Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT06652685 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

218

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: D5-PBCR(-) IA arm
DRUG: D5-PBCR(+) IA+Venetoclax arm

Sponsor

Ruijin Hospital